Revel Health Review
Appears to have shut downRevel Health is closed and is not taking new patients. It charged from $199 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Revel Health is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $199/mo. No longer offered.
See our top-rated GLP-1 providers →Revel Health sold compounded semaglutide and tirzepatide by telehealth, alongside NAD+, sermorelin and other longevity care. It is no longer selling. In October 2026 its site showed only a password-locked "Coming Soon" page with an email sign-up, and every page redirected there.
Vetted alternatives to Revel Health
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Revel Health at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Last published price
- $199/mo
- What it included
- Consult · Shipping · Medication
- Availability
- 45 states
- FDA status
- No FDA warning letters found
How Revel Health scores
Revel Health has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something Revel Health published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
5.0/10$199/month is exactly the median for compounded semaglutide across the sellers we compare.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
7.5/10No pharmacy is named for its prescriptions. It shows a price before asking for health information. It lists the states it serves.
Accessibility10%
9.2/10Serves 45 of 50 states.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Revel Health
Last checked October 2026- Checked the listed price across 2 dose or plan tiers
- Checked state coverage: 45 states
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Revel Health
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Medications Revel Health listed
Revel Health listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Peptides Revel Health offers
Revel Health sells peptides beyond the GLP-1s. Tap one to read what the evidence says about it.
Prices it published before closing
Prices re-verified
Preliminary placeholder — Revel doesn't show upfront pricing; confirm at checkout
Tirzepatide injection from $249/mo (first month $149)
In its favor
- Semaglutide cost $199 a month, exactly the $199 median for compounded semaglutide across the sellers we compare
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price included the medication, clinician visits and shipping
- Served 45 states
- We found no FDA warning letters issued to Revel Health
Against it
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Revel Health is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What Revel Health charged
Revel Health charged $199/month.
- Semaglutide: $199/month
- Compounded tirzepatide: $249/month
For compounded semaglutide, the median across the sellers we compare is $199/month, so Revel Health's $199 lands mid-market. Price is unlikely to be the deciding factor.
Bodybuilding Health+ dispenses semaglutide and tirzepatide from $179/month, which makes it the fair comparison to run before you commit here.
What Revel Health dispensed
Revel Health prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
Safety and disclosure
Revel Health told buyers its price before the medical questionnaire and the 45 states it served. We found no FDA warning letters issued to Revel Health. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
Revel Health is no longer taking new patients, so the choice is among the sellers that are still open. Belle Health is the nearest comparison we review, and worth reading alongside this.
The Bottom Line
Revel Health is closed and is not taking new patients. It charged from $199 a month.
Where Revel Health is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to Revel Health sets more sellers in the same category beside Revel Health on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Revel Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of October 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.